title: Effect of dutasteride on microvessel density in benign prostatic hyperplasia.
abstract: OBJECTIVE
  Dutasteride, a dual 5α-reductase inhibitor, is used to treat benign prostatic hyperplasia (BPH). However, its histopathological effects on the morphometrics of blood vessels and glands are still controversial. This study aimed to assess the histopathological effects of dutasteride in cases of BPH in a retrospective manner.
  
  
  METHODS
  Patients with BPH were administered 0.5 mg of dutasteride daily or left untreated prior to undergoing holmium laser enucleation of the prostate (HoLEP). After HoLEP, remaining prostatic peripheral tissue at the bladder neck and the apex was resected. Each specimen was subjected to hematoxylin/eosin and immunohistochemical staining for CD31, and microvessel density (MVD) was analyzed.
  
  
  RESULTS
  In the dutasteride-treated group (n=14), the mean duration of administration was 7.07±2.46 weeks. MVD was significantly lower at the bladder neck side in the dutasteride-treated group than in the control group (p=0.018).
  
  
  CONCLUSIONS
  The present study, to our knowledge for the first time, assessed MVD by evaluating the bladder neck and apex sides of the remaining prostatic peripheral tissue after HoLEP, allowing evaluation of MVD in more detail without intraoperative damage of the peripheral tissue, such as through heat denaturation. Dutasteride reduces MVD in the bladder neck side of the prostate among patients with BPH and may lead to decreased risk of perioperative prostatic urethral bleeding.
authors.affiliation: Department of Urology, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake-cho, Miyazaki 889-1692, Japan. satoru_sugie@med.miyazaki-u.ac.jp.
authors.forename: Satoru
authors.initials: S
authors.lastname: Sugie
authors.forename: Shoichiro
authors.initials: S
authors.lastname: Mukai
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Tsukino
authors.forename: Hideyasu
authors.initials: H
authors.lastname: Iwamoto
authors.forename: Takahiko
authors.initials: T
authors.lastname: Kobayashi
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Toda
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Kamoto
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D001378:Azasteroids / Q000494:pharmacology* / Q000627:therapeutic use; D016022:Case-Control Studies; D000068538:Dutasteride; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D055806:Microvessels / Q000187:drug effects* / Q000378:metabolism; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000378:metabolism; D011470:Prostatic Hyperplasia / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D058891:5-alpha Reductase Inhibitors; D001378:Azasteroids; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D000068538:Dutasteride
keywords: Microvessel density (MVD); benign prostatic hyperplasia; dutasteride; holmium laser enucleation of the prostate (HoLEP)